Tbo-filgrastim versus filgrastim for stem cell mobilization and engraftment in autologous hematopoietic stem cell transplant patients: A retrospective review.

Ashley L PotterBradley BeckSurachat Ngorsuraches

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)

Tbo-filgrastim demonstrates comparable efficacy with a cost savings benefit compared to filgrastim for autologous PBPC mobilization and stem cell engraftment.

Keyphrases

hematopoietic stem cell
stem cells
end stage renal disease
cell therapy
bone marrow
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
platelet rich plasma
chemotherapy induced
patient reported outcomes